Methods for antibody engineering

• US 7,462,697 B2
• Filed: 11/08/2004
• Issued: 12/09/2008
• Est. Priority Date: 11/08/2004
• Status: Active Grant

• Current Assignee: Epitomics Incorporated (Abcam Plc)
• Original Assignee: Epitomics Incorporated (Abcam Plc)
• Inventors: Yu, Guo-Liang, Couto, Fernando Jose Rebelo Do, Hendricks, Kristin B., Wallace, S. Ellen
• Primary Examiner(s): Blanchard; David J.
• Assistant Examiner(s): GUSSOW, ANNE
• Application Number:
  US10/984,473
• Publication Number:
  US 20060099204A1
• Time in Patent Office: 1,492 Days
• Field of Search: None
• US Class Current: 530/387.3
• CPC Class Codes: C07K 16/241 Tumor Necrosis Factors
• CPC Class Codes: C07K 16/467 Igs with modifications in the FR-residues only
• CPC Class Codes: G01N 33/577 involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens; G01N33/53 - G01N33/576 take precedence

Abstract

The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications.

Claims

1. A method for humanizing a rabbit antibody, comprising:

a) identifying a variation tolerant position in a parent rabbit antibody by comparing its amino acid sequence to the amino acid sequences of a plurality of related antibodies that are obtained from the same rabbit as said parent rabbit antibody, wherein said parent antibody and said related antibodies;

i. bind to the same antigen;

ii. each comprise heavy chain variable domains that have an overall amino acid sequence identity of at least 90% relative to one another;

iii. each comprise light chain variable domains that have an overall amino acid sequence identity of at least 90% relative to one another;

iv. have H3 CDRs that are identical in length and identical in sequence except for 0, 1 or 2 amino acid substitutions relative to one another;

v. have L3 CDRs that are identical in length and identical in sequence except for 0, 1 or 2 amino acid substitutions relative to one another;

b) aligning the amino acid sequence of said parent rabbit antibody with the amino acid sequence of a human antibody, wherein said human antibody is one of ten human antibodies that are most homologous to said parent rabbit antibody; and

c) substituting the amino acid present at said variation tolerant position with the corresponding amino acid of said human antibody to produce a humanized antibody.

2. The method of claim 1, wherein said method comprises:

identifying a variation tolerant position in a CDR region of said parent rabbit antibody by comparing the amino acid sequence of said CDR region with the amino acid sequences of corresponding CDR regions of said related antibodies,

aligning the amino acid sequence of said CDR region of said parent rabbit antibody with the amino acid sequence of the corresponding CDR region of said human antibody; and

substituting the amino acid present at said variation tolerant position in said CDR region of said parent rabbit antibody with the corresponding amino acid of said one of human antibody, to produce said humanized antibody.

3. The method of claim 1, wherein said method comprises:

a) identifying a variation tolerant position in a framework region of said parent rabbit antibody by comparing the amino acid sequence of said framework region to the amino acid sequences of corresponding framework regions of said related antibodies,

b) aligning the amino acid sequence of said framework region of said parent rabbit antibody with the amino acid sequence of the corresponding framework region of said human antibody; and

c) substituting the amino acid present at said variation tolerant position in said framework region of said parent rabbit antibody with the corresponding amino acid of said human antibody.

4. The method of claim 1, wherein the amino acid of variation tolerant position is substituted by an amino acid present at a corresponding position in one of said related antibodies.

5. The method of claim 1, wherein said aligning employs human germline antibody amino acid sequences.

6. The method of claim 1, wherein said comparing includes aligning the amino acid sequence of the variable domains of said parent rabbit antibody and said related antibodies to make a sequence alignment.

7. The method of claim 1, wherein said plurality of related antibodies is at least 3 related antibodies.

8. The method of claim 1, wherein at least two non-contiguous amino acids of said parent antibody are substituted.

9. A method of screening for a rabbit monoclonal antibody having altered affinity or avidity, comprising:

a) identifying a variation tolerant position in a parent rabbit monoclonal antibody by comparing its amino acid sequence to the amino acid sequences of a plurality of related monoclonal antibodies that are obtained from the same rabbit as said parent rabbit antibody, wherein said parent antibody and said related antibodies are produced by cells that have a common B cell ancestor in said rabbit, wherein antibodies produced by cells that have a common B cell ancestor;

i. bind to the same antigen;

ii. each comprise heavy chain variable domains that have an overall amino acid sequence identity of at least 90% relative to one another;

iii. each comprise light chain variable domains that have an overall amino acid sequence identity of at least 90% relative to one another;

iv. have H3 CDRs that are identical in length and identical in sequence except for 0, 1 or 2 amino acid substitutions relative to one another;

v. have L3 CDRs that are identical in length and identical in sequence except for 0, 1 or 2 amino acid substitutions relative to one another;

b) substituting an amino acid at said variation tolerant position with a different amino acid to produce a test antibody; and

c) screening said test antibody for altered affinity or avidity.

10. The method of claim 9, wherein said method comprises:

a) identifying a variation tolerant position in a CDR region of said parent rabbit monoclonal antibody by comparing the amino acid sequence of said CDR region to the amino acid sequences of corresponding CDR regions of said related antibodies,

b) aligning the amino acid sequence of said CDR region of said parent rabbit monoclonal antibody with the amino acid sequence of the corresponding CDR region of a human antibody; and

c) substituting the amino acid present at said variation tolerant position in said CDR region of said parent rabbit antibody with the corresponding amino acid of said human antibody to produce said test antibody.

11. The method of claim 9, wherein said method comprises:

a) identifying a variation tolerant position in framework regions of said parent rabbit monoclonal antibody by comparing its amino acid sequence to the amino acid sequences of corresponding framework regions of said related antibodies,

b) aligning the amino acid sequence of framework regions of said parent rabbit monoclonal antibody with the amino acid sequence of the corresponding framework regions of a human antibody; and

c) substituting the amino acid present at said variation tolerant position in said framework region of said parent rabbit antibody with the corresponding amino acid of said human antibody.

12. The method of claim 9, wherein said test antibody is screened for increased affinity, avidity or specificity.

13. The method of claim 9, wherein said screening is done by ELISA.

14. The method of claim 9, wherein the amino acid of variation tolerant position is substituted by a different amino acid at a corresponding position in one of said related monoclonal antibodies.

15. The method of claim 9, wherein said human antibody is the most homologous to said parent rabbit antibody.